Johnson & Johnson expects $2.5 billion in global sales from Covid vaccine this year

Earnings

In this article

In this photo illustration a Johnson & Johnson logo is seen in front of a medical syringe and a vial with coronavirus vaccine.
Pavlo Gonchar | SOPA Images | LightRocket | Getty Images

Johnson & Johnson said Wednesday it expects to sell $2.5 billion of its Covid-19 vaccine, even as concerns mount over the shot’s effectiveness against the delta variant.

In releasing its second-quarter financial results, the company also reported earnings and revenue that beat Wall Street’s expectations.

Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv:

  • Adjusted EPS: $2.48 per share vs $2.27 expected.
  • Revenue: $23.31 billion vs $22.21 billion expected.

The company’s share price was up nearly 1% in premarket trading following the report.

This is a developing story. Please check back for updates.

Products You May Like

Articles You May Like

What The IRS Can Learn From The Florida Bar Tax Section: Comments To Clawback Proposed Regulations
The New Medicare Drug Bill Is Big, But Seniors Won’t See Many Of Its Benefits For Years
Los Angeles Home Once Owned By Marilyn Monroe Lists For $6.9 Million
Addressing Social Security’s funding woes will take political compromise, Biden nominee to advisory board says
How do people in Asia-Pacific feel about travel right now? It depends on where they live